Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
Keyword(s):
2020 ◽
Vol 21
◽
pp. 9-16
◽
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2006 ◽
Vol 98
(24)
◽
pp. 1786-1794
◽
Keyword(s):
2019 ◽
Vol 14
(2)
◽
pp. 125-136
◽
Keyword(s):
Keyword(s):
Keyword(s):